ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA To Limit Radiation Doses from Medical Imaging

February 12, 2010

Low-Dose Warfarin Prevents Blood Clots, NIH Study Finds

February 28, 2003

Hudis’s Address At ASCO 2014: On Value & Commitment

June 6, 2014

Concepts Approved For New Technology In Computers, Recompetition

November 6, 1987

NCAB to Get NCI Bypass Budget May 13; DeVita Tells Centers That Is Where “Our Philosophy Can Be Found”

May 3, 1985

In Brief: ACCC Annual Meeting Scheduled March 16-19; Lao to Head Pharmacology At Pittsburgh

January 1, 1988